摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(氯甲基)-3-[3-(三氟甲基)苯基]-1,2,4-恶二唑 | 844498-80-2

中文名称
5-(氯甲基)-3-[3-(三氟甲基)苯基]-1,2,4-恶二唑
中文别名
——
英文名称
5-(chloromethyl)-3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole
英文别名
5-(Chloromethyl)-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
5-(氯甲基)-3-[3-(三氟甲基)苯基]-1,2,4-恶二唑化学式
CAS
844498-80-2
化学式
C10H6ClF3N2O
mdl
MFCD06200906
分子量
262.619
InChiKey
SQEQCLQTYOGYPH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    87-90/0.2mm

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    17
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2934999090

SDS

SDS:0fcf0843729b3d41b0d67fce4c9c79c1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-(Chloromethyl)-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-(Chloromethyl)-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole
CAS number: 844498-80-2

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H6ClF3N2O
Molecular weight: 262.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    5-(氯甲基)-3-[3-(三氟甲基)苯基]-1,2,4-恶二唑盐酸potassium carbonate 作用下, 以 乙醇N,N-二甲基甲酰胺 为溶剂, 生成 1,3-dipropyl-8-(1-((3-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-1H-pyrazol-4-yl)-1H-purine-2,6(3H,7H)-dione
    参考文献:
    名称:
    作为高亲和力和选择性A2B腺苷受体拮抗剂的新型1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物。
    摘要:
    合成了一系列新的1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物作为A(2B)-AdoR拮抗剂,并评估了它们与A(2B)的结合亲和力),A(1),A(2A)和A(3)-AdoR。8-(1-(((3-苯基-1,2,4-恶二唑-5-基)甲基)-1H-吡唑-4-基)-1,3-二丙基-1H-嘌呤-2,6( 3H,7H)-二酮(4)对A(2B)-AdoR与A(1),A(2A)和A(3)-AdoRs的亲和力(K(i)= 1 nM)和选择性高( A(1)/ A(2B),A(2A)/ A(2B)和A(3)/ A(2B)选择性比分别为370、1100和480)。本文介绍了这类新型化合物的合成和SAR。
    DOI:
    10.1016/j.bmcl.2005.10.002
  • 作为产物:
    参考文献:
    名称:
    作为高亲和力和选择性A2B腺苷受体拮抗剂的新型1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物。
    摘要:
    合成了一系列新的1,3-二丙基-8-(1-杂芳基甲基-1H-吡唑-4-基)-黄嘌呤衍生物作为A(2B)-AdoR拮抗剂,并评估了它们与A(2B)的结合亲和力),A(1),A(2A)和A(3)-AdoR。8-(1-(((3-苯基-1,2,4-恶二唑-5-基)甲基)-1H-吡唑-4-基)-1,3-二丙基-1H-嘌呤-2,6( 3H,7H)-二酮(4)对A(2B)-AdoR与A(1),A(2A)和A(3)-AdoRs的亲和力(K(i)= 1 nM)和选择性高( A(1)/ A(2B),A(2A)/ A(2B)和A(3)/ A(2B)选择性比分别为370、1100和480)。本文介绍了这类新型化合物的合成和SAR。
    DOI:
    10.1016/j.bmcl.2005.10.002
点击查看最新优质反应信息

文献信息

  • Development of Small Molecules with a Noncanonical Binding Mode to HIV-1 Trans Activation Response (TAR) RNA
    作者:Fardokht A. Abulwerdi、Matthew D. Shortridge、Joanna Sztuba-Solinska、Robert Wilson、Stuart F. J. Le Grice、Gabriele Varani、John S. Schneekloth
    DOI:10.1021/acs.jmedchem.6b01450
    日期:2016.12.22
    molecules that bind to RNA potently and specifically are relatively rare. The study of molecules that bind to the HIV-1 transactivation response (TAR) hairpin, a cis-acting HIV genomic element, has long been an important model system for the chemistry of targeting RNA. Here we report the synthesis, biochemical, and structural evaluation of a series of molecules that bind to HIV-1 TAR RNA. A promising analogue
    有效结合RNA的小分子相对较少。长期以来,对与HIV-1反式激活应答(TAR)发夹(一种顺式作用的HIV基因组元件)结合的分子的研究一直是靶向RNA化学的重要模型系统。在这里,我们报告了一系列与HIV-1 TAR RNA结合的分子的合成,生化和结构评估。一个有前途的类似物15保留了最初命中的TAR结合亲和力,并用40μM的IC 50取代了Tat衍生的肽。可溶性类似物2的NMR表征显示此类化合物的非规范结合模式。最后,评估2和15通过引物延伸(SHAPE)分析的选择性2'-羟基酰化反应,表明在体外合成的365-nt HIV-1 5'-非翻译区(UTR)内与TAR结合的特异性。因此,这些化合物表现出与TAR相互作用的新颖且特定的模式,为RNA配体设计提供了重要建议。
  • Synthesis and Biological Activity of 3-Aryl-5-(aryloxymethyl)-1,2,4-oxadiazoles
    作者:A. A. Shetnev、E. A. Vasilieva、I. K. Proskurina、A. S. Forostyanko、S. I. Presnukhina、M. V. Tarasenko、A. S. Lebedev、S. A. Ivanovskii、A. D. Kotov
    DOI:10.1134/s1070428022030071
    日期:2022.3
    preparative procedure has been developed for the synthesis of a series of new medicinally relevant 3-aryl-5-(aryloxymethyl)-1,2,4-oxadiazoles in 46–66% yields by alkylation of substituted phenols with 3-aryl-5-(chloromethyl)-1,2,4-oxadiazoles in the system K2CO3/KI/DMF. Poorly studied 3-R-4H-1,2,4-oxadiazin-5(6H)-ones were synthesized by a new method based on the reaction of methyl chloroacetate with amidoximes
    摘要 已开发出一种制备方法,通过用 3-aryl-5 对取代酚进行烷基化,以 46-66% 的收率合成一系列新的药用相关 3-aryl-5-(aryloxymethyl)-1,2,4-oxadiazoles -(氯甲基)-1,2,4-恶二唑体系K 2 CO 3 /KI/DMF。研究较少的3-R-4 H -1,2,4-oxadiazin-5(6 H )-ones 采用氯乙酸甲酯与偕胺肟在超碱性体系t -BuONa/DMSO反应的新方法合成。合成的浓度高达 250 μg/mL 的化合物对金黄色葡萄球菌、枯草芽孢杆菌、大肠杆菌等敏感菌株无抗菌活性。和荧光假单胞菌,这可能表明它们对人体肠道和粘液菌群的毒性较低。
  • Heterocyclic GPR40 Modulators
    申请人:Beck Hilary
    公开号:US20080090840A1
    公开(公告)日:2008-04-17
    The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    本发明提供了一些化合物,例如用于治疗受试者的代谢紊乱。此类化合物具有一般式I,其中变量的定义在此提供。本发明还提供了包含这些化合物的组合物以及使用这些化合物制备药物和治疗代谢紊乱(例如II型糖尿病)的方法。
  • HETEROCYCLIC GPR40 MODULATORS
    申请人:Beck Hilary
    公开号:US20100075974A1
    公开(公告)日:2010-03-25
    The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    本发明提供了一些化合物,例如,用于治疗受试者的代谢紊乱。这些化合物具有一般式I:其中变量的定义在此提供。本发明还提供了包括这些化合物的组合物,以及使用这些化合物制备药物和治疗代谢紊乱的方法,例如类型II糖尿病。
  • Organophosphate, Verfahren zu ihrer Herstellung sowie diese enthaltende Schädlingsbekämpfungsmittel
    申请人:NIHON TOKUSHU NOYAKU SEIZO K.K.
    公开号:EP0081151A1
    公开(公告)日:1983-06-15
    Die vorliegende Erfindung betrifft neue Organophosphate, ein Verfahren zu ihrer Herstellung, sowie diese enthaltende Schädlingsgekämpfungsmittel. Die neuen Organophosphate haben die nachstehende Formel in der R1 für eine Alkyl-Gruppe mit 3 bis 4 Kohlenstoff-Atomen oder eine Alkoxyethyl-Gruppe mit einer Alkoxy-Struktureinheit mit 1 bis 4 Kohlenstoff-Atomen, R2 für ein Wasserstoff-Atom oder eine Methyl-Gruppe und R3 für eine Alkyl-Gruppe mit 1 bis 4 Kohlenstoff-Atomen oder eine Phenyl-Gruppe, die durch mindestens einen Substituenten ausgewählt aus der aus einem Halogen-Atom, einer Trifluoromethyl-Gruppe, Nitro-Gruppe, Alkyl-Gruppe mit 1 bis 4 Kohlenstoffatomen und Alkoxy-Gruppe mit 1 bis 4 Kohlenstoffatomen bestehenden Gruppe substituiert sein kann, stehen.
    本发明涉及新型有机膦酸盐、其制备方法以及含有这些有机膦酸盐的农药。 新型有机膦酸盐具有下式,其中 R1 代表具有 3 至 4 个碳原子的烷基或具有 1 至 4 个碳原子的烷氧基的烷氧基乙基,R2 代表氢原子或甲基,R3 代表具有 1 至 4 个碳原子的烷基或苯基,该苯基可被至少一个取代基取代,该取代基选自由卤素原子、三氟甲基、硝基、具有 1 至 4 个碳原子的烷基和具有 1 至 4 个碳原子的烷氧基组成的组。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺